Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...